Exposure to Toxic DustNCT07485608
Reducing Lead Dust Exposure in Older Housing
A study testing portable air filtration systems in people with Exposure to Toxic Dust and Elevated Blood Lead Levels, run by Michigan State University at 1 site in United States.
Trial summary
The objective of this study is to assess the effectiveness of portable air filtration (PAF) for mitigating lead dust exposures and reducing childhood blood lead levels in older housing. Read more about this study
- Who is it for?
- Ages Up to 7 years
- Conditions the study is for
- Exposure to Toxic Dust, Elevated Blood Lead Levels
- What is being tested?
- portable air filtration systems
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2022to 30 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 7 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- child under seven years of age with BLL >5 µg/dL,
- child must reside in housing built before 1978, and
- child must sleep at home during participation in the two month-long study.
Who cannot join
- anything in child's health history that could affect the study results, or
- any circumstance that could interfere with guardian's/parent's ability to consent and/or participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Michigan State University
East Lansing, Michigan, 48824
Tuan Nguyen, BS, 517-884-2043, nguye620@msu.edu
About this study
Official title: Reducing Lead Dust Exposure and Childhood Blood Lead Levels in Older Housing in Michigan
The objective of this study is to assess the effectiveness of portable air filtration (PAF) for mitigating lead dust exposures and reducing childhood blood lead levels in older housing.
Read the detailed description
In close collaboration with local health departments, this project will enroll 40 participants who (1) reside in housing built before 1970, and (2) have children under six years of age with blood lead levels (BLL) >5 μg/dL. Specific objectives include (1) assess reduction of Pb dust exposure via the intervention, (2) assess the ability of PAF to reduce childhood BLL indirectly via reductions in Pb dust exposure, and (3) develop evidence-based exposure reduction guidance for wider public use of PAF. The project team will measure Pb levels in (1) suspended dust, (2) floor dust, and (3) children's blood before the start and finish of the two-month-long intervention as well as at the midpoint.
- Conditions
- Exposure to Toxic Dust, Elevated Blood Lead Levels
- Being tested
- portable air filtration systems
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
portable air filtration systemsOther
Two portable air filtration units placed in subjects' homes (one in child's bedroom and one in living room) will be kept running for two months.
| Study group | Role | What they receive |
|---|---|---|
| air filtration systems | Experimental | Portable air filtration units will be kept running in homes for two months. Receives: Other: portable air filtration systems |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in blood lead level
change in blood lead level (in ug/dL).
Measured: After two months at the end of the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2026
- Study start1 Dec 2022
- Primary completion31 Jul 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Exposure to Toxic DustStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Michigan State University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Masako Morishita, Michigan State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07485608
- Sponsor's protocol ID
- MILTS0025-21
- Status last verified
- Mar 2026
- First submitted
- 2 May 2023
- Last updated
- 20 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reducing Lead Dust Exposure and Childhood Blood Lead Levels in Older Housing in Michigan
- ClinicalTrials.gov ID
- NCT07485608
- Acronym / sponsor ID
- MILTS0025-21
- Conditions
- Exposure to Toxic Dust, Elevated Blood Lead Levels
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Michigan State UniversityUniversity, hospital or other
- Study start
- 1 Dec 2022 (actual)
- Primary completion
- 31 Jul 2026 (estimated)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 20 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to assess the effectiveness of portable air filtration (PAF) for mitigating lead dust exposures and reducing childhood blood lead levels in older housing.
Detailed description
In close collaboration with local health departments, this project will enroll 40 participants who (1) reside in housing built before 1970, and (2) have children under six years of age with blood lead levels (BLL) >5 μg/dL. Specific objectives include (1) assess reduction of Pb dust exposure via the intervention, (2) assess the ability of PAF to reduce childhood BLL indirectly via reductions in Pb dust exposure, and (3) develop evidence-based exposure reduction guidance for wider public use of PAF. The project team will measure Pb levels in (1) suspended dust, (2) floor dust, and (3) children's blood before the start and finish of the two-month-long intervention as well as at the midpoint.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| air filtration systems | Experimental | Other: portable air filtration systemsPortable air filtration units will be kept running in homes for two months. |
Who may qualify
- Ages
- Up to 7 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- child under seven years of age with BLL >5 µg/dL,
- child must reside in housing built before 1978, and
- child must sleep at home during participation in the two month-long study.
Key exclusion criteria (2 listed)
- anything in child's health history that could affect the study results, or
- any circumstance that could interfere with guardian's/parent's ability to consent and/or participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| portable air filtration systemsTwo portable air filtration units placed in subjects' homes (one in child's bedroom and one in living room) will be kept running for two months. | Other | air filtration systems |
Primary outcome
Change in blood lead level
Time frame: After two months at the end of the intervention
change in blood lead level (in ug/dL).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing portable air filtration systems in people with Exposure to Toxic Dust and Elevated Blood Lead Levels, run by Michigan State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tuan Nguyen, BS (517-884-2043, nguye620@msu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in blood lead level (time frame: After two months at the end of the intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.